Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )

Informations projet

I-CREATE

N° de convention de subvention: 190121193

DOI 10.3030/190121193

Projet clôturé

Date de signature de la CE 11 Novembre 2022

Date de début 1 Juillet 2022

Date de fin 31 Decembre 2023

Financé au titre de

• The European Innovation Council (EIC)

Coût total € 5 073 000,00

Contribution de l’UE € 2 100 000,00

Coordonné par

TILT BIOTHERAPEUTICS OY
Finland

Livrables

Documents, reports (1)

Interim clinical data from at least 3 patients

Deliverable relates to reporting of interim results of the ongoing clinical studies T115 T215

Websites, patent fillings, videos etc. (2)

First-patients treated

Update on the trial progress in the first study sites in Docrates finland and Mayo Clinic Minnesota

IND/clinical trial approved (T776)

IND approved for T776 headneck cancer clinical trial